Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)
Henry Lik‐Yuen Chan(Radiant Research (United States)), Elizabeth Cooney(Bristol-Myers Squibb (United States)), Sang Hoon Ahn(Yonsei University), Seng Gee Lim(National University of Singapore), Patrick Marcellin(Inserm), Harry L.A. Janssen(Erasmus MC), Stefan Zeuzem(Goethe University Frankfurt), Linda Critelli(Bristol-Myers Squibb (United States)), Pei‐Jer Chen(National Taiwan University), Lawrence Serfaty(Inserm), Cheng‐Yuan Peng(China Medical University), Carla S. Coffin(University of Calgary), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Dong Xu(Bristol-Myers Squibb (United States)), David Cohen, Ting‐Tsung Chang(National Cheng Kung University Hospital), David Wong(University Health Network)
Cited by 106
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
|New England Journal of Medicine|2004|1.1k